Jun 30 |
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
|
Jun 28 |
Savara prices ~$100M stock offering
|
Jun 28 |
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
|
Jun 26 |
Savara: Today's Data 'Win' Rouses Market All Too Briefly
|
Jun 26 |
Savara surges after late-stage trial win for lead asset against rare lung disease
|
Jun 26 |
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Jun 26 |
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Jun 19 |
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
|
Jun 11 |
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
|
Jun 7 |
Savara: The Binary Bet On Phase 3 Data
|